Incyte has completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, adding the late-stage von Willebrand disease candidate VGA039 to its hematology portfolio. The transaction gives Incyte full ownership of the investigational monoclonal antibody, which is in Phase 3 development and could offer a once-monthly subcutaneous preventive treatment for patients with the inherited bleeding disorder. Incyte said the acquisition supports its broader strategy of expanding its hematology franchise with differentiated therapies targeting significant unmet medical needs.
Expanding the Hematology Pipeline
The deal involves an upfront payment of $1.25 billion for all outstanding shares of Vega Therapeutics. Star Therapeutics may receive up to $750 million in further payments if agreed sales milestones are achieved. Incyte expects to recognize the transaction as a one-time research and development expense in its third-quarter and full-year 2026 GAAP and non-GAAP financial results.
VGA039 is being developed for von Willebrand disease, the most common inherited bleeding disorder. The condition is caused by low or defective levels of von Willebrand factor, a protein that helps blood clot properly. Patients may experience excessive bleeding of varying frequency and severity, which can affect daily life and complicate surgical or medical procedures.
Existing preventive treatments can require multiple intravenous infusions each week, including factor replacement therapies. Incyte believes VGA039 could provide a less burdensome option because it is designed for self-administration through a monthly subcutaneous injection. If approved, the therapy could become the first once-monthly subcutaneous prophylactic treatment available for people with von Willebrand disease.
A Novel Approach to Bleeding Disorders
VGA039 targets Protein S, a naturally occurring protein that plays a role in the regulation of blood clotting. The therapy is designed to improve hemostasis by supporting platelet attachment and increasing fibrin deposition, both of which can help the body control bleeding. Incyte and Vega believe the mechanism could have potential applications across several bleeding disorders beyond von Willebrand disease.
The treatment candidate has received several U.S. Food and Drug Administration designations, including Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations. These programs can support more efficient development and regulatory engagement, although they do not guarantee marketing approval. Incyte will now take responsibility for advancing VGA039 through the remaining stages of clinical development and potential regulatory review.
VGA039 is currently being evaluated in the Phase 3 VIVID-6 study, a global single-arm crossover trial. The study is examining the safety and efficacy of subcutaneous VGA039 as preventive treatment for bleeding in patients across all forms of von Willebrand disease, including those with a high disease burden. The program is intended to assess whether the therapy can reduce bleeding while improving treatment convenience compared with frequent intravenous regimens.
Strategic Significance for Incyte
Bill Meury, Incyte’s chief executive officer, said the acquisition adds a promising late-stage hematology asset to the company’s portfolio. He described VGA039 as a strategic fit for Incyte’s hematology franchise and said the company aims to expand its presence in bleeding disorders. Incyte also said it expects to work with Vega’s employees as it progresses the Phase 3 program.
The acquisition continues Incyte’s effort to broaden its business across hematology, oncology, inflammation, and autoimmunity. Buying a Phase 3 asset gives the company access to a program that is closer to potential commercialization than an earlier-stage discovery candidate, but it also leaves Incyte exposed to clinical, regulatory, and commercial risks. The value of the transaction will depend on trial outcomes, approval decisions, patient adoption, competition, and the company’s ability to execute a successful launch.
Lazard acted as financial adviser to Incyte, while Goodwin Procter served as legal counsel. Evercore and Morgan Stanley advised Star Therapeutics financially, and Fenwick & West acted as the company’s legal counsel. The completed transaction transfers responsibility for VGA039’s development, regulatory strategy, and potential commercialization to Incyte.
Incyte’s acquisition of Vega Therapeutics gives the company a late-stage therapy candidate aimed at a substantial unmet need in inherited bleeding disorders. VGA039’s Protein S-targeting mechanism and potential once-monthly subcutaneous dosing could differentiate it from current preventive options if clinical data remain positive. The deal positions Incyte to pursue a new category within hematology while it works to convert a promising Phase 3 program into an approved treatment.